scholarly journals Chemical and Mechanical Actions of Drugs Active Group Used in COVID-19 Treatment

Author(s):  
Suhayla K. Mohammed ◽  
Mzahim M. Taha ◽  
Ekhlass M. Taha

With the new global outbreak of the novel COVID-19, control and treatment has become critical. There is no medication proven to be effective for the treatment of severe acute respiratory syndrome which is caused by COVID-19 according to the World Health Organization (WHO) reports. Most studies that have been done on this time are clinical trials. Those studies used several drugs like lopinavir, ritonavir, nebulized alpha-interferon and, aminoquinolines. The mechanism of action is not well known so far. This review studies the metabolites of the tested drugs with different kinds of the viral membrane which merging proteins based on mechanical criteria.

2020 ◽  
Vol 10 (4) ◽  
pp. 4-5
Author(s):  
Marco Aurélio M Freire ◽  
Usaamah Khan ◽  
Daniel Falcão

In December 2019, the first reports of the Coronavirus Disease 2019 (COVID-19) emerged in Wuhan, Hubei Province, China, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with a subsequent outbreak rapidly spreading globally. Since then, the COVID-19 pandemic has impacted society worldwide, and the SAR-CoV-2 virus continues to spread, by infecting more than 55 million people and causing over one million and three-hundred thousand deaths to date. On January 30th, 2020, the World Health Organization (WHO) declared COVID-19 a Public Health Emergency of International concern, having a vast impact on people's behavior, personal relationships, jobs, and the global economy, besides causing a severe burden to the healthcare system.


Author(s):  
MONAJI SANJANA REDDY

Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) is another name given to pandemic disease COVID-19 that is caused by a newly discovered coronavirus. People infected with coronavirus will experience mild-to-moderate respiratory illness, and it can be seen in a serious stage when comorbidities include along with it. This is now creating a huge pandemic situation all over the world with a huge rate of sufferers, that is, around 9.06 million around the world and about 440 k in India till today according to the World Health Organization. This is a serious condition that should be solved with vaccine only as coronavirus is undergoing mutation it makes difficult to invent a vaccine for it. So far, about 200 genetic mutations have been discovered across the world also in these 198 mutations appeared independently more than once. Due to this pandemic situation, there are so many clinical trials going on in discovering vaccines. Recently, after many trails conducting favipiravir are found to be the most successful in treating any stage of SARS-CoV-2. This article focuses completely on this area, along with its mechanism, side effects, uses, and contraindications.


Pathogens ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 32
Author(s):  
Giovanni Di Guardo

With over 80 million cases, and 1,800,000 deaths reported at the end of 2020 by the World Health Organization, the “CoronaVirus Disease-2019” (CoViD-19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), should be viewed as a global catastrophe [...]


2021 ◽  
Vol 8 (2) ◽  
pp. 01-03
Author(s):  
Ashish Gujrathi

Coronavirus (COVID-19) was recognized in late December in Hubei province of Wuhan city in China. This highly contagious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from humans to humans. After the first case in Wuhan, the disease rapidly spread to other parts of the globe. On March 11, 2020, the World Health Organization (WHO) made an assessment that COVID-19 can be characterized as a pandemic. Thus, social-distancing became an important measure to stop the spread of this disease. Various countries across the world adopted nationwide lockdowns. This led to a completely new scenario for the world, where every business in each industry faced new challenges and witnessed new opportunities. Similarly, the medical personal protective industry, a vital part of the healthcare sector, also witnessed new growth opportunities.


2021 ◽  
Vol 4 (2) ◽  
Author(s):  
Salman Tahir Shafi

In January 2020, the pathogen was identified and named by the World Health Organization as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2). The consequent SARS-CoV-2-related disease was defined as coronavirus disease 2019 (COVID-19). As data emerged about characteristics of the disease, it was found to be associated with increased risk of acute kidney injury (AKI). We explore the recent literature and reports emerging from the epicenters of the pandemic to help our viewers understand the nature of AKI among these patients. 


2021 ◽  
Vol 10 (1) ◽  
pp. 36-41
Author(s):  
Seyed Hesamaddin Banihashemi ◽  
Ahmadreza Karimi ◽  
Hasti Nikourazm ◽  
Behnaz Bahmanyar ◽  
Dariush Hooshyar

The severe acute respiratory syndrome coronavirus 2 virus and its associated disease, called coronavirus disease 2019 (COVID-19), first appeared in Wuhan, China in December 2019 and quickly spread around the world. Coronavirus was officially named COVID-19 by the World Health Organization and was recognized as a pandemic due to its rapid spread worldwide. Based on the published data, it is hoped to provide a source for later studies and to help prevent and control the contagious COVID-19 and its characteristics, and considerations that surgeons and medical staff must observe during the epidemic.


2020 ◽  
Vol 25 (32) ◽  
Author(s):  
Erik Alm ◽  
Eeva K Broberg ◽  
Thomas Connor ◽  
Emma B Hodcroft ◽  
Andrey B Komissarov ◽  
...  

We show the distribution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic clades over time and between countries and outline potential genomic surveillance objectives. We applied three genomic nomenclature systems to all sequence data from the World Health Organization European Region available until 10 July 2020. We highlight the importance of real-time sequencing and data dissemination in a pandemic situation, compare the nomenclatures and lay a foundation for future European genomic surveillance of SARS-CoV-2.


2020 ◽  
pp. 10.1212/CPJ.0000000000000910 ◽  
Author(s):  
Francisco Antunes Dias ◽  
Ana Luiza Nunes Cunha ◽  
Patrícia Maria Pedrosa Pantoja ◽  
Carolina Lavigne Moreira ◽  
Pedro José Tomaselli ◽  
...  

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged in Wuhan, China, in December 2019,1 and the World Health Organization has declared it a pandemic in March 2020. Since then, severe neurological complications associated with COVID-19 have been described, including encephalitis and stroke.2,3 Recently, it has been recognized that acute neuropathies may also occur.4,5 Herein, we report a COVID-19 patient presenting an acute refractory painful polyradiculoneuritis.


2020 ◽  
Vol 27 (3) ◽  
Author(s):  
Darlan Da S Candido ◽  
Alexander Watts ◽  
Leandro Abade ◽  
Moritz U G Kraemer ◽  
Oliver G Pybus ◽  
...  

The global outbreak caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been declared a pandemic by the World Health Organization. As the number of imported SARS-CoV-2 cases is on the rise in Brazil, we use incidence and historical air travel data to estimate the most important routes of importation into the country.


2020 ◽  
Vol 29 (155) ◽  
pp. 200068 ◽  
Author(s):  
Martina Ferioli ◽  
Cecilia Cisternino ◽  
Valentina Leo ◽  
Lara Pisani ◽  
Paolo Palange ◽  
...  

The World Health Organization has recently defined the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection a pandemic. The infection, that may cause a potentially very severe respiratory disease, now called coronavirus disease 2019 (COVID-19), has airborne transmission via droplets. The rate of transmission is quite high, higher than common influenza. Healthcare workers are at high risk of contracting the infection particularly when applying respiratory devices such as oxygen cannulas or noninvasive ventilation. The aim of this article is to provide evidence-based recommendations for the correct use of “respiratory devices” in the COVID-19 emergency and protect healthcare workers from contracting the SARS-CoV-2 infection.


Sign in / Sign up

Export Citation Format

Share Document